CFTR MODULATION WITH TEZACAFTOR/IVACAFTOR IN PATIENTS HETEROZYGOUS FOR F508DEL AND A RESIDUAL FUNCTION MUTATION

被引：0
|
作者：
Rowe, Steven M. [1 ]
Davies, Jane [2 ]
机构：
[1] Univ Alabama Birmingham, Med, Birmingham, AL USA
[2] Imperial Coll London, London, England
来源：
PEDIATRIC PULMONOLOGY | 2017年 / 52卷
关键词：
CYSTIC-FIBROSIS; POTENTIATOR; IVACAFTOR;
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
S14.2
引用
收藏
页码：S175 / S176
页数：2
相关论文
共 50 条
  • [1] RETROSPECTIVE ANALYSIS OF PHYSIOLOGICAL RESPONSE PATTERNS TO TEZACAFTOR/IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR F508DEL-CFTR OR HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION
    Ingenito, E.
    Nair, N.
    Yi, B.
    Lekstrom-Himes, J.
    Elborn, J. S.
    Rowe, S. M.
    THORAX, 2018, 73 : A42 - A43
  • [2] RETROSPECTIVE ANALYSIS OF PHYSIOLOGICAL RESPONSE PATTERNS TO TEZACAFTOR/IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR F508DEL-CFTR OR HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION
    Ingenito, E.
    Nair, N.
    Yi, B.
    Lekstrom-Himes, J.
    Elborn, J.
    Rowe, S. M.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 198 - 198
  • [3] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
    Donaldson, Scott H.
    Pilewski, Joseph M.
    Griese, Matthias
    Cooke, Jon
    Viswanathan, Lakshmi
    Tullis, Elizabeth
    Davies, Jane C.
    Lekstrom-Himes, Julie A.
    Wang, Linda T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 214 - 224
  • [4] Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation
    Vincken, Stefanie
    Verbanck, Sylvia
    Braun, Sue
    Buyck, Nathalie
    Knoop, Christiane
    Vanderhelst, Eef
    ACTA CLINICA BELGICA, 2023, 78 (04) : 280 - 284
  • [5] Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles
    Graeber, Simon Y.
    Vitzthum, Constanze
    Pallenberg, Sophia T.
    Naehrlich, Lutz
    Stahl, Mirjam
    Rohrbach, Alexander
    Drescher, Marika
    Minso, Rebecca
    Ringshausen, Felix C.
    Rueckes-Nilges, Claudia
    Klajda, Jan
    Berges, Julian
    Yu, Yin
    Scheuermann, Heike
    Hirtz, Stephanie
    Sommerburg, Olaf
    Dittrich, Anna-Maria
    Tuemmler, Burkhard
    Mall, Marcus A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (05) : 540 - 549
  • [6] EFFECTS OF LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR F508DEL CFTR MUTATION
    Melotti, P.
    Tridello, G.
    Pintani, E.
    Meneghelli, I
    Volpi, S.
    Spinelli, E.
    D'Orazio, C.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 242 - 242
  • [7] A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
    Sawicki, Gregory S.
    Chilvers, Mark
    McNamara, John
    Naehrlich, Lutz
    Saunders, Clare
    Sermet-Gaudelus, Isabelle
    Wainwright, Claire E.
    Ahluwalia, Neil
    Campbell, Daniel
    Harris, R. Scott
    Paz-Diaz, Hildegarde
    Shih, Judy L.
    Davies, Jane C.
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (04) : 675 - 683
  • [8] EFFECTS OF TEZACAFTOR/IVACAFTOR TREATMENT IN PATIENTS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION: PATIENT-REPORTED OUTCOMES IN A PHASE 3 RANDOMIZED, CONTROLLED TRIAL
    Chuang, C.
    Rizio, A.
    Loop, B.
    Lekstrom-Himes, J.
    You, X.
    Kosinski, M.
    Rendas-Baum, R.
    Davies, J. C.
    Rowe, S. M.
    Yang, Y.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 264 - 264
  • [9] DETECTION OF CORRECTED F508DEL CFTR IN PATIENTS TREATED WITH IVACAFTOR/LUMACAFTOR
    Ostmann, A. J.
    Ray, K.
    Thornton, K.
    Rowe, S.
    Solomon, G.
    Clancy, J.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 295 - 295
  • [10] Long-term Safety and Efficacy of Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis Homozygous for F508del-CFTR or Heterozygous for F508del and a Residual Function Mutation: First Interim Analysis Results of a Phase 3, Open-label, Rollover Study
    Flume, P. A.
    Owen, C. A.
    Brown, C. D.
    Wang, L.
    Jain, M.
    Yuan, Z.
    Lekstrom-Himes, J.
    Keating, C. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
12345